Gilead Sciences has announced EMA validation for a parallel accelerated review of lenacapavir’s MAA and EU-M4all applications ...

得益于抗逆转录病毒疗法的发展，HIV感染已经从致命疾病转变为可控的慢性病，患者只要每日坚持服药，就可获得与正常人相当的寿命。然而根据世界卫生组织（WHO）的统计，仅在2023年，全球仍有近4000万艾滋病患者，其中有130万新增感染，约63万人死于艾 ...

在这一革命性技术的背后，是一项令人惊艳的生物学突破。lenacapavir采用皮下植入式长效缓释的黑科技，能够在体内持续发挥作用，确保高危人群获得持久的保护。其三维抗病毒靶向机制的示意图展现了其对细胞的精准攻击，让病毒无处遁形。更令人振奋的是，在近期的临床试验中，南非高危人群的防护率高达99.7%，而性少数群体的用药依从性提升幅度也达到了惊人的300%。这意味着，lenacapavir不仅加强了预 ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...

美国食品与药物管理局（FDA）周二表示，将优先受理 吉利德科学 公司（Gilead Science）一年两次Lenacapavir预防HIV的新药申请。

近年来，HIV治疗领域不断取得突破，从每日服药到长效注射，从单一疗法到联合用药，患者拥有了更多治疗选择。 与此同时，更多在研HIV新药管线还在继续推进，致力于为患者带来更多高效、安全、便利的治疗选择。

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application submissions for lenacapavir for human immunodeficiency virus (HIV) prevention.

The US Food and Drug Administration (FDA) has accepted Gilead’s new drug application (NDA) for lenacapavir and set a ...

Gilead Sciences, Inc. (NASDAQ:GILD)首席财务官Andrew Dickinson近期进行了一系列公司股票交易。2月12日，Dickinson以每股102.22美元的价格出售了137,676股Gilead ...